650 related articles for article (PubMed ID: 25612245)
1. Multimodal Imaging and Choroidal Volumetric Changes After Half-fluence PDT in Central Serous Chorioretinopathy.
Munk MR; Shah R; Pappas F; Baddar D; Wong B; Jampol LM; Fawzi AA
Curr Eye Res; 2016; 41(1):97-106. PubMed ID: 25612245
[TBL] [Abstract][Full Text] [Related]
2. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
[TBL] [Abstract][Full Text] [Related]
3. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.
Maruko I; Iida T; Sugano Y; Ojima A; Ogasawara M; Spaide RF
Ophthalmology; 2010 Sep; 117(9):1792-9. PubMed ID: 20472289
[TBL] [Abstract][Full Text] [Related]
4. Reduced-fluence photodynamic therapy for subfoveal serous pigment epithelial detachment with choroidal vascular hyperpermeability.
Goto S; Gomi F; Ueno C; Nishida K
Am J Ophthalmol; 2012 Nov; 154(5):865-871.e1. PubMed ID: 22840480
[TBL] [Abstract][Full Text] [Related]
5. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.
Nicolò M; Zoli D; Musolino M; Traverso CE
Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy.
Lim SH; Chang W; Sagong M
Eye (Lond); 2013 Mar; 27(3):353-62. PubMed ID: 23449515
[TBL] [Abstract][Full Text] [Related]
7. Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy.
Pryds A; Larsen M
Acta Ophthalmol; 2012 Dec; 90(8):738-43. PubMed ID: 21586096
[TBL] [Abstract][Full Text] [Related]
8. Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy.
Inoue R; Sawa M; Tsujikawa M; Gomi F
Am J Ophthalmol; 2010 Mar; 149(3):441-6.e1-2. PubMed ID: 20172070
[TBL] [Abstract][Full Text] [Related]
9. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Cheng CK; Chang CK; Peng CH
Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
[TBL] [Abstract][Full Text] [Related]
10. Assessment of choroidal topographic changes by swept source optical coherence tomography after photodynamic therapy for central serous chorioretinopathy.
Razavi S; Souied EH; Cavallero E; Weber M; Querques G
Am J Ophthalmol; 2014 Apr; 157(4):852-60. PubMed ID: 24412124
[TBL] [Abstract][Full Text] [Related]
11. Effect of Photodynamic Therapy on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy.
Xu Y; Su Y; Li L; Qi H; Zheng H; Chen C
Ophthalmologica; 2017; 237(3):167-172. PubMed ID: 28171871
[TBL] [Abstract][Full Text] [Related]
12. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy.
Lim JI; Glassman AR; Aiello LP; Chakravarthy U; Flaxel CJ; Spaide RF;
Ophthalmology; 2014 May; 121(5):1073-8. PubMed ID: 24439758
[TBL] [Abstract][Full Text] [Related]
13. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
[TBL] [Abstract][Full Text] [Related]
14. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
[TBL] [Abstract][Full Text] [Related]
15. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
Matušková V; Vysloužilová D; Uher M
Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
[TBL] [Abstract][Full Text] [Related]
16. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M
Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
[TBL] [Abstract][Full Text] [Related]
17. Retinal Pigment Epithelial Features in Central Serous Chorioretinopathy Identified by Polarization-Sensitive Optical Coherence Tomography.
Roberts P; Baumann B; Lammer J; Gerendas B; Kroisamer J; Bühl W; Pircher M; Hitzenberger CK; Schmidt-Erfurth U; Sacu S
Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):1595-603. PubMed ID: 27046123
[TBL] [Abstract][Full Text] [Related]
18. Early choriocapillaris changes after half-fluence photodynamic therapy in chronic central serous chorioretinopathy evaluated by optical coherence tomography angiography: Preliminary results.
Demircan A; Yesilkaya C; Alkin Z
Photodiagnosis Photodyn Ther; 2018 Mar; 21():375-378. PubMed ID: 29409857
[TBL] [Abstract][Full Text] [Related]
19. Chronic central serous chorioretinopathy imaged by optical coherence tomographic angiography.
Quaranta-El Maftouhi M; El Maftouhi A; Eandi CM
Am J Ophthalmol; 2015 Sep; 160(3):581-587.e1. PubMed ID: 26133250
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy.
Smretschnig E; Hagen S; Glittenberg C; Ristl R; Krebs I; Binder S; Ansari-Shahrezaei S
Eye (Lond); 2016 Jun; 30(6):805-11. PubMed ID: 26965012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
